Editorial
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 28, 2015; 21(24): 7343-7348
Published online Jun 28, 2015. doi: 10.3748/wjg.v21.i24.7343
Perioperative chemotherapy for resectable gastric cancer: MAGIC and beyond
Audrey H Choi, Joseph Kim, Joseph Chao
Audrey H Choi, Joseph Kim, Department of Surgical Oncology, City of Hope, Duarte, CA 91010, United States
Joseph Chao, Department of Medical Oncology, City of Hope, Duarte, CA 91010, United States
Author contributions: All authors contributed to the manuscript.
Supported by National Cancer Institute of the National Institutes of Health under award, No. NIH 5K12CA001727-20.
Conflict-of-interest: The authors do not have any relevant disclosures.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Joseph Chao, MD, Department of Medical Oncology, City of Hope, 1500 E. Duarte Rd, Duarte, CA 91010, United States. jchao@coh.org
Telephone: +1-626-2189200 Fax: +1-626-3018233
Received: January 29, 2015
Peer-review started: January 30, 2015
First decision: March 10, 2015
Revised: March 26, 2015
Accepted: May 2, 2015
Article in press: May 4, 2015
Published online: June 28, 2015
Processing time: 152 Days and 13.2 Hours
Core Tip

Core tip: Although multiple phase III trials have been performed around the world, no standard of care exists for the treatment of gastric cancer. We reviewed the existing high-level evidence supporting the use of neoadjuvant and adjuvant chemotherapy, chemoradiation, and anti-HER2 therapies in gastric cancer, as well as provide a clinical framework for the treatment of gastric cancer patients at our institution based on these studies. Also highlighted in this editorial are current clinical trials in progress and future directions of gastric cancer research based on next generation sequencing data.